Zevra Therapeutics, Inc. Common Stock (ZVRA)

Price$10.61

Value ScoreC

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)17.93%

Price vs S&P 500 (4W)-4.66%

VGM Score67.46

Market Capitalization$647.90M

P/E Ratio (Annual)7.78x

All Metrics

Book Value / Share (Quarterly)$3.48

P/TBV (Annual)3.40x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)116.72%

Cash Flow / Share (Quarterly)$0.20

Price vs S&P 500 (YTD)10.26%

Gross Margin (TTM)97.90%

Net Profit Margin (TTM)101.58%

EPS (TTM)$2.15

10-Day Avg Trading Volume2.00M

EPS Excl Extra (TTM)$2.15

Revenue Growth (5Y)51.61%

EPS (Annual)$1.45

ROI (Annual)38.43%

Gross Margin (Annual)96.37%

Net Profit Margin (5Y Avg)-192.68%

Cash / Share (Quarterly)$3.39

P/E Basic Excl Extra (TTM)5.22x

Revenue Growth QoQ (YoY)77.54%

P/E Normalized (Annual)7.78x

ROA (Last FY)29.23%

Revenue Growth TTM (YoY)201.29%

EBITD / Share (TTM)$-0.05

ROE (5Y Avg)-68.35%

Operating Margin (TTM)-4.44%

Cash Flow / Share (Annual)$-0.04

P/B Ratio3.15x

P/B Ratio (Quarterly)2.66x

Net Income / Employee (Annual)$1,364,400

EV / Revenue (TTM)4.52x

Net Interest Coverage (TTM)99.27x

ROA (TTM)45.60%

EV / EBITDA (TTM)3.51x

EPS Incl Extra (Annual)$1.45

Current Ratio (Annual)5.68x

Quick Ratio (Quarterly)4.74x

3-Month Avg Trading Volume1.26M

52-Week Price Return20.16%

P/E Incl Extra (TTM)5.22x

Revenue / Employee (TTM)$2,004,700

Tangible BV / Share (Quarterly)$3.38

P/S Ratio (Annual)6.09x

Asset Turnover (Annual)0.37x

52-Week High$13.16

Operating Margin (5Y Avg)-208.77%

EPS Excl Extra (Annual)$1.45

CapEx CAGR (5Y)94.50%

26-Week Price Return25.86%

Quick Ratio (Annual)5.46x

13-Week Price Return20.71%

Total Debt / Equity (Annual)0.40x

Current Ratio (Quarterly)4.89x

Enterprise Value$552.31M

Revenue / Share Growth (5Y)-11.05%

Asset Turnover (TTM)0.45x

Revenue / Employee (Annual)$1,745,400

Pretax Margin (Annual)81.41%

Cash / Share (Annual)$3.36

3-Month Return Std Dev64.64%

Net Income / Employee (TTM)$2,036,400

ROE (Last FY)53.82%

Net Interest Coverage (Annual)10.98x

EPS Basic Excl Extra (Annual)$1.45

P/FCF (TTM)40.98x

Receivables Turnover (TTM)7.05x

EV / Free Cash Flow (TTM)46.04x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$2.15

Receivables Turnover (Annual)6.49x

ROI (TTM)62.52%

P/S Ratio (TTM)5.30x

Pretax Margin (5Y Avg)-180.49%

Revenue / Share (Annual)$1.86

Tangible BV / Share (Annual)$2.61

Forward P/E13.46x

Price vs S&P 500 (52W)-4.21%

P/E Ratio (TTM)5.22x

Year-to-Date Return18.42%

5-Day Price Return-7.66%

EPS Normalized (Annual)$1.45

ROA (5Y Avg)-19.83%

Net Profit Margin (Annual)78.17%

Month-to-Date Return-8.46%

Cash Flow / Share (TTM)$-1.15

EBITD / Share (Annual)$-1.03

Operating Margin (Annual)-59.12%

LT Debt / Equity (Annual)0.40x

P/CF (TTM)50.75x

ROI (5Y Avg)-31.78%

P/E Excl Extra (TTM)5.22x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$2.15

P/TBV (Quarterly)2.74x

P/B Ratio (Annual)3.26x

Inventory Turnover (TTM)1.05x

Pretax Margin (TTM)109.09%

Book Value / Share (Annual)$2.72

Price vs S&P 500 (13W)12.45%

Beta0.93x

P/FCF (Annual)62.66x

Revenue / Share (TTM)$2.03

ROE (TTM)81.34%

52-Week Low$7.16

vGradeC

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.18est. 0.08

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.21

4.27

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ZVRAZevra Therapeutics, Inc. Common Stock	C	A	B	$10.61
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Zevra Therapeutics is a biopharmaceutical company focused on developing and commercializing transformational therapies for rare diseases with limited or no existing treatment options. The company employs data-driven strategies to overcome complex drug development challenges and accelerate the delivery of novel therapeutics to underserved patient populations.